Skip to content
Facebook Instagram Linkedin

LifeScienceHistory.com

History made daily

  • Home
  • DirectoryExpand
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • News and History
  • Cartoons
  • Small World
  • Earth is a RockExpand
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
LifeScienceHistory.com
History made daily
Home / pediatric - Page 4

pediatric

U.S. FDA approves cell therapy for patients with blood cancers to reduce risk of infection after stem cell transplantation
FDA | Life Science History

U.S. FDA approves cell therapy for patients with blood cancers to reduce risk of infection after stem cell transplantation

On Apr. 17, 2023, the U.S. FDA approved Gamida Cell’s Omisirge (omidubicel-onlv), a substantially modified allogeneic (donor) cord…

Read More U.S. FDA approves cell therapy for patients with blood cancers to reduce risk of infection after stem cell transplantationContinue

Amphastar Pharmaceuticals received FDA approval for Naloxone hydrochloride nasal spray
Biotechnology | FDA | Medicine | Pharmaceutical | Therapeutics

Amphastar Pharmaceuticals received FDA approval for Naloxone hydrochloride nasal spray

On Mar. 8, 2023, Amphastar Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) had granted approval…

Read More Amphastar Pharmaceuticals received FDA approval for Naloxone hydrochloride nasal sprayContinue

Pfizer and BioNTech submitted for U.S. EUA of Omicron BA.4/BA.5-adapted bivalent COVID-19 booster in children under 5 years
Biotechnology | COVID-19 | FDA | Infectious Disease | Vaccine

Pfizer and BioNTech submitted for U.S. EUA of Omicron BA.4/BA.5-adapted bivalent COVID-19 booster in children under 5 years

On Mar. 1, 2023, BioNTech and Pfizer announced that they had submitted an application to the U.S. Food…

Read More Pfizer and BioNTech submitted for U.S. EUA of Omicron BA.4/BA.5-adapted bivalent COVID-19 booster in children under 5 yearsContinue

EMA Committee for Medicinal Products for Human Use rcommended use of Moderna’s BA.1 bivalent COVID-19 booster in children in the EU
Biotechnology | COVID-19 | Infectious Disease | Vaccine

EMA Committee for Medicinal Products for Human Use rcommended use of Moderna’s BA.1 bivalent COVID-19 booster in children in the EU

On Dec. 16, 2022, Moderna announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use…

Read More EMA Committee for Medicinal Products for Human Use rcommended use of Moderna’s BA.1 bivalent COVID-19 booster in children in the EUContinue

FDA granted approval to atezolizumab for alveolar soft part sarcoma
Biotechnology | FDA | Oncology | Therapeutics

FDA granted approval to atezolizumab for alveolar soft part sarcoma

On Dec. 9, 2022, the U.S. Food and Drug Administration (FDA) approved Genentech’s atezolizumab (Tecentriq) for adult and…

Read More FDA granted approval to atezolizumab for alveolar soft part sarcomaContinue

FDA approved first drug that can delay onset of Type 1 Diabetes
Biotechnology | Disease | FDA | Therapeutics

FDA approved first drug that can delay onset of Type 1 Diabetes

On Nov. 17, 2022, the U.S. Food and Drug Administration (FDA) approved Tzield (teplizumab-mzwv) injection to delay the…

Read More FDA approved first drug that can delay onset of Type 1 DiabetesContinue

FDA approved first cellbBased gene therapy to treat adult and pediatric patients with Beta-thalassemia
Life Science History

FDA approved first cellbBased gene therapy to treat adult and pediatric patients with Beta-thalassemia

On Aug. 17, 2022, the U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel) developed by bluebird bio,…

Read More FDA approved first cellbBased gene therapy to treat adult and pediatric patients with Beta-thalassemiaContinue

Novavax filed supplement to a New Drug submission in Canada for Nuvaxovid COVID-19 vaccine for adolescents
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Novavax filed supplement to a New Drug submission in Canada for Nuvaxovid COVID-19 vaccine for adolescents

On Jun. 23 2022, Novavax announced the filing of a Supplement to a New Drug Submission with Health…

Read More Novavax filed supplement to a New Drug submission in Canada for Nuvaxovid COVID-19 vaccine for adolescentsContinue

Veklury (Remdesivir) was first and only approved treatment for pediatric patients under 12 years of age with COVID-19
Biotechnology | COVID-19 | FDA | Infectious Disease

Veklury (Remdesivir) was first and only approved treatment for pediatric patients under 12 years of age with COVID-19

On Apr. 25, 2022, Gilead Sciences announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental…

Read More Veklury (Remdesivir) was first and only approved treatment for pediatric patients under 12 years of age with COVID-19Continue

Fred Hutch and Seattle Cancer Care Alliance unite, reshaped relationship with UW Medicine
Biotechnology | Diagnostics | Non-Profit Research | Oncology | Radiology | Therapeutics | Women's Health

Fred Hutch and Seattle Cancer Care Alliance unite, reshaped relationship with UW Medicine

On Apr. 1, 2022, the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance (SCCA) announced a…

Read More Fred Hutch and Seattle Cancer Care Alliance unite, reshaped relationship with UW MedicineContinue

Novavax submitted request to expand conditional Marketing Authorization of COVID-19 vaccine in the EU to adolescents
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Novavax submitted request to expand conditional Marketing Authorization of COVID-19 vaccine in the EU to adolescents

On Mar. 31, 2022, Novavax announced submission of its request to expand the conditional marketing authorization (CMA) of…

Read More Novavax submitted request to expand conditional Marketing Authorization of COVID-19 vaccine in the EU to adolescentsContinue

Moderna announced COVID-19 vaccine phase 2/3 study in children 6 months to Under 6 years met Its primary endpoint
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Moderna announced COVID-19 vaccine phase 2/3 study in children 6 months to Under 6 years met Its primary endpoint

On Mar. 23, 2022, Moderna announced positive interim data from the Phase 2/3 KidCOVE study of the Moderna…

Read More Moderna announced COVID-19 vaccine phase 2/3 study in children 6 months to Under 6 years met Its primary endpointContinue

Researchers generated the first complete, gapless sequence of a human genome
Biotechnology | Diagnostics | Genomics | Medicine | Therapeutics

Researchers generated the first complete, gapless sequence of a human genome

On Mar. 21, 2022, in support of the Cancer Moonshot goal of fostering data sharing in cancer research,…

Read More Researchers generated the first complete, gapless sequence of a human genomeContinue

NIH launched program to offer molecular characterization of childhood cancers
Life Science History

NIH launched program to offer molecular characterization of childhood cancers

On Mar. 21, 2022, in support of the Cancer Moonshot? goal of fostering data sharing in cancer research,…

Read More NIH launched program to offer molecular characterization of childhood cancersContinue

Pfizer initiated phase 2/3 study of novel COVID-19 oral treatment in pediatric participants
Biotechnology | COVID-19 | Infectious Disease | Therapeutics

Pfizer initiated phase 2/3 study of novel COVID-19 oral treatment in pediatric participants

On Mar. 9, 2022, Pfizer announced that it had initiated a Phase 2/3 study, EPIC-PEDS (Evaluation of ProteaseInhibition…

Read More Pfizer initiated phase 2/3 study of novel COVID-19 oral treatment in pediatric participantsContinue

Gilead reported phase 2/3 interim data evaluating safety, tolerability and clinical outcomes of Veklury (Remdesivir) in pediatric patients with COVID-19
Biotechnology | COVID-19 | Therapeutics

Gilead reported phase 2/3 interim data evaluating safety, tolerability and clinical outcomes of Veklury (Remdesivir) in pediatric patients with COVID-19

On Feb. 11, 2022, Gilead Sciences announced new data from an interim analysis of its ongoing, Phase 2/3…

Read More Gilead reported phase 2/3 interim data evaluating safety, tolerability and clinical outcomes of Veklury (Remdesivir) in pediatric patients with COVID-19Continue

Veklury (Remdesivir) retained antiviral activity against Omicron, Delta and other emergent SARS-CoV-2 variants
Biotechnology | COVID-19 | Therapeutics

Veklury (Remdesivir) retained antiviral activity against Omicron, Delta and other emergent SARS-CoV-2 variants

On Feb. 11, 2022, Gilead Sciences announced new data from an interim analysis of its ongoing, Phase 2/3…

Read More Veklury (Remdesivir) retained antiviral activity against Omicron, Delta and other emergent SARS-CoV-2 variantsContinue

Novavax announced positive results of COVID-19 vaccine in pediatric population of PREVENT-19 phase 3 clinical trial
Biotechnology | COVID-19 | Infectious Disease | Nanotechnology | Vaccine

Novavax announced positive results of COVID-19 vaccine in pediatric population of PREVENT-19 phase 3 clinical trial

On Feb. 10, 2022, Novavax announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, achieved its primary effectiveness…

Read More Novavax announced positive results of COVID-19 vaccine in pediatric population of PREVENT-19 phase 3 clinical trialContinue

InteliSwab COVID-19 rapid tests receive U.S. FDA authorization for pediatric use
Biotechnology | COVID-19 | Diagnostics | FDA | Infectious Disease | Life Science History

InteliSwab COVID-19 rapid tests receive U.S. FDA authorization for pediatric use

On Jan. 31, 2022, OraSure Technologies announced that its InteliSwab COVID-19 rapid tests had been authorized by the…

Read More InteliSwab COVID-19 rapid tests receive U.S. FDA authorization for pediatric useContinue

FDA approved Veklury (Remdesivir) for treatment of non-hospitalized patients at high risk for COVID-19 disease progression
COVID-19 | FDA | Life Science History

FDA approved Veklury (Remdesivir) for treatment of non-hospitalized patients at high risk for COVID-19 disease progression

On Jan. 20, 2022, Gilead Sciences announced that the U.S. Food and Drug Administration had granted expedited approval…

Read More FDA approved Veklury (Remdesivir) for treatment of non-hospitalized patients at high risk for COVID-19 disease progressionContinue

Pfizer received U.S. FDA Emergency Use Authorization for novel COVID-19 oral antiviral treatment
Biotechnology | COVID-19 | FDA | Infectious Disease | Therapeutics

Pfizer received U.S. FDA Emergency Use Authorization for novel COVID-19 oral antiviral treatment

On Dec. 22, 2021, Pfizer announced that the U.S. Food and Drug Administration (FDA) had authorized the emergency…

Read More Pfizer received U.S. FDA Emergency Use Authorization for novel COVID-19 oral antiviral treatmentContinue

FDA authorized long-acting monoclonal antibodies for pre-exposure prevention of COVID-19 in certain individuals
COVID-19 | Life Science History

FDA authorized long-acting monoclonal antibodies for pre-exposure prevention of COVID-19 in certain individuals

On Dec. 8, 2021, the U.S. Food and Drug Administration issued an emergency use authorization for AstraZenecaメs Evusheld…

Read More FDA authorized long-acting monoclonal antibodies for pre-exposure prevention of COVID-19 in certain individualsContinue

SIGA announced Health Canada regulatory approval of Oral TPOXX
Biotechnology | FDA | Infectious Disease | Therapeutics | Vaccine

SIGA announced Health Canada regulatory approval of Oral TPOXX

On Dec. 1, 2021, SIGA Technologies announced that Health Canada had approved oral TPOXX (tecovirimat) as an extraordinary…

Read More SIGA announced Health Canada regulatory approval of Oral TPOXXContinue

Global progress against measles threatened amidst COVID-19 pandemic
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Vaccine | WHO

Global progress against measles threatened amidst COVID-19 pandemic

On Nov. 10, 2021, the World Health Organization (WHO) announced that while reported measles cases had fallen compared…

Read More Global progress against measles threatened amidst COVID-19 pandemicContinue

Moderna filed to expand the conditional Marketing Authorization for COVID-19 vaccine in the EU to include children ages 6-11 years
Biotechnology | COVID-19 | FDA | Infectious Disease | Vaccine

Moderna filed to expand the conditional Marketing Authorization for COVID-19 vaccine in the EU to include children ages 6-11 years

On Nov. 9, 2021, Moderna announced that it has submitted for a variation to the conditional marketing authorization…

Read More Moderna filed to expand the conditional Marketing Authorization for COVID-19 vaccine in the EU to include children ages 6-11 yearsContinue

Pfizer and BioNTech provided U.S. Government an additional 50 million pediatric doses of COVID-19 vaccine
Biotechnology | COVID-19 | Pharmaceutical | Therapeutics | Vaccine

Pfizer and BioNTech provided U.S. Government an additional 50 million pediatric doses of COVID-19 vaccine

On Oct. 28, 2021, Pfizer and BioNTech announced that the U.S. government had purchased 50 million more doses…

Read More Pfizer and BioNTech provided U.S. Government an additional 50 million pediatric doses of COVID-19 vaccineContinue

U.S. FDA approved expanded indication of Gilead’s Biktarvy for Treatment of HIV-1 in pediatric populations
Biotechnology | FDA | HIV | Therapeutics

U.S. FDA approved expanded indication of Gilead’s Biktarvy for Treatment of HIV-1 in pediatric populations

On Oct. 18, 2021, Gilead Sciences announced that the Food and Drug Administration had approved a new low-dose…

Read More U.S. FDA approved expanded indication of Gilead’s Biktarvy for Treatment of HIV-1 in pediatric populationsContinue

LogicBio Therapeutics announced early clinical trial results demonstrated first-ever in vivo genome editing in children
Genomics | Life Science History

LogicBio Therapeutics announced early clinical trial results demonstrated first-ever in vivo genome editing in children

On Oct. 18, 2021, LogicBio Therapeutics announced clinical trial results that demonstrated the first-ever in vivo genome editing…

Read More LogicBio Therapeutics announced early clinical trial results demonstrated first-ever in vivo genome editing in childrenContinue

Washington University School of Medicine in St. Louis led pediatric COVID-19 vaccine trial launched
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Washington University School of Medicine in St. Louis led pediatric COVID-19 vaccine trial launched

On Oct. 6, 2021, Washington University School of Medicine announced the start of a pediatric COVID-19 vaccine clinical…

Read More Washington University School of Medicine in St. Louis led pediatric COVID-19 vaccine trial launchedContinue

Humanigen submitted all planned modules forpotential conditional Marketing Authorization from UKメs MHRA
COVID-19 | Life Science History

Humanigen submitted all planned modules forpotential conditional Marketing Authorization from UKメs MHRA

On Oct. 1, 2021, Humanigen announced it had submitted all the planned modules as well as a risk…

Read More Humanigen submitted all planned modules forpotential conditional Marketing Authorization from UKメs MHRAContinue

Page navigation

Previous PagePrevious 1 2 3 4 5 6 … 8 Next PageNext
  • Categories
  • Timeline
  • Aesthetics
  • Agriculture
  • Artificial Intelligence
  • Biology
  • Biotechnology
  • Cardiology
  • Cartoons – Historical
  • Cartoons – Original
  • CDC
  • CDMO
  • Chemistry
  • Clinical Research
  • Cloning
  • CMO
  • COVID-19
  • CRISPR
  • CRO
  • Cryogenic
  • Dentistry
  • Diagnostics
  • Disease
  • Energy
  • Environmental
  • EPA
  • FDA
  • Forestry
  • Genomics
  • HIV
  • Infectious Disease
  • Influenza
  • IRB
  • Life Science History
  • Marine Science
  • Materials
  • Measles
  • Medical Device
  • Medicine
  • Nanotechnology
  • Neurology
  • NIH
  • Non-Profit Research
  • Nutraceuticals
  • olfactory
  • Oncology
  • Ophthalmogy
  • Organ Transplant
  • Orthopedic
  • Other
  • Pharmaceutical
  • Plague
  • Polio
  • Prehistory
  • Quantum
  • Radiology
  • Rare Disease
  • Stem Cell
  • Therapeutics
  • U.S. Congress
  • Uncategorized
  • USDA
  • Vaccine
  • Veterinary
  • WHO
  • Women's Health
  • 2026
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002
  • 2001
  • 2000
  • 1999
  • 1998
  • 1997
  • 1996
  • 1995
  • 1994
  • 1993
  • 1992
  • 1991
  • 1990
  • 1989
  • 1988
  • 1987
  • 1986
  • 1985
  • 1984
  • 1983
  • 1982
  • 1981
  • 1980
  • 1979
  • 1978
  • 1977
  • 1976
  • 1975
  • 1974
  • 1973
  • 1972
  • 1971
  • 1970
  • 1969
  • 1968
  • 1967
  • 1966
  • 1965
  • 1964
  • 1963
  • 1962
  • 1961
  • 1960
  • 1959
  • 1958
  • 1957
  • 1956
  • 1955
  • 1954
  • 1953
  • 1952
  • 1951
  • 1950
  • 1949
  • 1948
  • 1947
  • 1946
  • 1945
  • 1944
  • 1943
  • 1942
  • 1941
  • 1940
  • 1939
  • 1938
  • 1937
  • 1936
  • 1935
  • 1934
  • 1933
  • 1932
  • 1931
  • 1930
  • 1929
  • 1928
  • 1927
  • 1926
  • 1925
  • 1924
  • 1923
  • 1922
  • 1921
  • 1920
  • 1919
  • 1918
  • 1917
  • 1916
  • 1915
  • 1914
  • 1913
  • 1912
  • 1911
  • 1910
  • 1909
  • 1908
  • 1907
  • 1906
  • 1905
  • 1904
  • 1903
  • 1902
  • 1901
  • 1900
  • 1899
  • 1898
  • 1897
  • 1896
  • 1895
  • 1894
  • 1893
  • 1892
  • 1891
  • 1890
  • 1889
  • 1888
  • 1887
  • 1886
  • 1885
  • 1884
  • 1883
  • 1882
  • 1881
  • 1880
  • 1879
  • 1878
  • 1877
  • 1876
  • 1875
  • 1874
  • 1873
  • 1872
  • 1871
  • 1870
  • 1869
  • 1868
  • 1867
  • 1866
  • 1865
  • 1864
  • 1863
  • 1862
  • 1861
  • 1860
  • 1859
  • 1858
  • 1857
  • 1856
  • 1855
  • 1854
  • 1853
  • 1852
  • 1851
  • 1850
  • 1849
  • 1848
  • 1847
  • 1846
  • 1845
  • 1844
  • 1843
  • 1842
  • 1840
  • 1839
  • 1838
  • 1837
  • 1836
  • 1834
  • 1833
  • 1832
  • 1831
  • 1830
  • 1828
  • 1827
  • 1826
  • 1825
  • 1824
  • 1823
  • 1820
  • 1819
  • 1818
  • 1817
  • 1816
  • 1813
  • 1811
  • 1810
  • 1809
  • 1808
  • 1804
  • 1802
  • 1801
  • 1800
  • 1799
  • 1798
  • 1796
  • 1795
  • 1794
  • 1793
  • 1790
  • 1789
  • 1788
  • 1786
  • 1785
  • 1784
  • 1782
  • 1781
  • 1777
  • 1769
  • 1765
  • 1761
  • 1753
  • 1751
  • 1749
  • 1747
  • 1746
  • 1743
  • 1741
  • 1738
  • 1727
  • 1723
  • 1721
  • 1720
  • 1718
  • 1716
  • 1710
  • 1697
  • 1693
  • 1683
  • 1674
  • 1667
  • 1666
  • 1665
  • 1664
  • 1663
  • 1658
  • 1656
  • 1647
  • 1636
  • 1634
  • 1629
  • 1621
  • 1603
  • 1580
  • 1521
  • 1510
  • 1403
  • 1377
  • 1370
  • 1363
  • 1348
  • 1346
  • 1322
  • 1285
  • 1202
  • 1200
  • 1179
  • 1100
  • 1050
  • 541
  • 470
  • 1
Subscribe to E-History

Subscribe

* indicates required

LifeScienceHistory.com

LifeScienceHistory.com Where history is made daily, is a comprehensive companion of life science. Simply put, we dig history and we mine data.

More

  • About
  • Life Science Heroes

Advertising

  • Banner Advertising

Legal

  • Privacy Policy
  • Terms of Use

© 2026 LifeScienceHistory.com by James Web Design

Facebook Instagram Linkedin
  • Home
  • Directory
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • News and History
  • Cartoons
  • Small World
  • Earth is a Rock
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
Search